You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Refractory to azacitidine and venetoclax

Showing 1 - 25 of 9,438
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia Refractory Trial in Lyon (NP137, Azacitidine Injection, Venetoclax)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Lyon, France
    Centre Léon Bérard
Nov 30, 2023

Acute Myeloid Leukemia Trial (Dasatinib)

Not yet recruiting
  • Acute Myeloid Leukemia
  • (no location specified)
Sep 20, 2023

Refractory/Relapse Acute Myeloid Leukemia Trial in Kunming (Venetoclax)

Recruiting
  • Refractory/Relapse Acute Myeloid Leukemia
  • Kunming, Yunnan, China
    Department of Hematology,920th Hospital of Joint Logistic Suppor
Mar 28, 2023

Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation Trial (Ziftomenib, Venetoclax,

Not yet recruiting
  • Acute Myeloid Leukemia
  • +10 more
  • (no location specified)
Feb 17, 2023

Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia Trial in Xiamen (venetoclax combining chidamide and

Recruiting
  • Leukemia, Myeloid, Acute
  • +2 more
  • venetoclax combining chidamide and azacitidine (VCA)
  • Xiamen, Fujian, China
    Bing Xu
Aug 1, 2022

Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia Trial

Recruiting
  • Recurrent Chronic Myelomonocytic Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 21, 2022

MDS, Myeloproliferative Chronic Myelomonocytic Leukemia Trial in Houston (Cladribine, Cytarabine, Venetoclax)

Recruiting
  • Myelodysplastic Syndromes
  • Myeloproliferative Chronic Myelomonocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2022

Venetoclax Combined With Azacitidine Plus Homoharringtonine, Venetoclax Combined With Azacitidine Trial in Guangzhou (VEN

Recruiting
  • Venetoclax Combined With Azacitidine Plus Homoharringtonine
  • Venetoclax Combined With Azacitidine
  • VEN combined with azacitidine plus homoharringtonine
  • VEN combined with azacitidine
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Jul 9, 2022

Acute Myeloid Leukemia, Relapsed Adult AML Trial (Lintuzumab-Ac225, Venetoclax, Azacitidine)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Relapsed Adult AML
  • Lintuzumab-Ac225
  • +2 more
  • (no location specified)
Feb 22, 2022

Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Minimal Residual Disease Trial (Venetoclax, Decitabine,

Not yet recruiting
  • Relapsed Acute Myeloid Leukemia
  • +2 more
  • Venetoclax, Decitabine, Azacytidine, Cytarabine
  • (no location specified)
May 4, 2022

MDS, de Novo, MDS, Secondary, MDS, Previously Treated Trial in Boston (Venetoclax, Azacitidine, Cytarabine)

Recruiting
  • Myelodysplastic Syndromes, de Novo
  • +10 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 23, 2023

Elderly AML Patients, Unfit, New-diagnosis AML, Acute Myeloid Leukemia Trial in Kunming (Experimental: Venetoclax in combination

Not yet recruiting
  • Elderly AML Patients
  • +4 more
  • Experimental: Venetoclax in combination with Decitabine (+-sorafenib)
  • Active Comparator: Standard dose of Venetoclax + Azacitidine
  • Kunming, Yunnan, China
    The Second Affiliated Hospital of Kunming Medical University.
Oct 3, 2023

Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells Trial in

Recruiting
  • Acute Myeloid Leukemia
  • +7 more
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
May 16, 2022

Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome Trial in Philadelphia

Recruiting
  • Myelodysplastic Syndrome
  • +2 more
  • Navitoclax
  • +6 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Feb 2, 2023

Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, MDS Trial in Finland (Bexmarilimab, Azacitidine, Venetoclax)

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Helsinki, Finland
  • +3 more
Jun 29, 2022

Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 16, 2021

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody

Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Anti-OX40 Agonist Monoclonal Antibody PF-04518600
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 25, 2022

Chronic Myelomonocytic Leukemia Trial in Houston (Azacitidine, Tamibarotene, Venetoclax)

Not yet recruiting
  • Chronic Myelomonocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Oct 10, 2023

Acute Myeloid Leukemia Trial in Kunming (Venetoclax in Combination With Azacitidine and HA Regimen)

Recruiting
  • Acute Myeloid Leukemia
  • Venetoclax in Combination With Azacitidine and HA Regimen
  • Kunming, Yunnan, China
    The Second Affiliated Hospital of Kunming Medical University.
Jul 10, 2023

Hematopoietic and Lymphoid Cell Tumor, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Trial in Houston

Active, not recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 6, 2022

AML, Adult, Minimal Residual Disease Trial (MRD assessment)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • MRD assessment
  • (no location specified)
Oct 13, 2023

Acute Myeloid Leukemia, Adult Trial in Houston (ADI-PEG 20)

Recruiting
  • Acute Myeloid Leukemia, Adult
  • ADI-PEG 20
  • Houston, Texas
    MD Anderson Cancer Center
Sep 29, 2022

Acute Myeloid Leukemia Trial in Houston (Azacitidine, Venetoclax, NK Cells)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Houston, Texas
    M.D. Anderson Cancer Center
Apr 17, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial in Beijing

Recruiting
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
  • Best-Available Therapy(BAT) Regimen
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Oct 10, 2023

Hypomethylating Agent, Venetoclax, Myeloid Malignancy Trial in Shanghai (Venetoclax, Azacitidine or decitabine)

Recruiting
  • Hypomethylating Agent
  • +2 more
  • Shanghai, Shanghai, China
    Shanghai Jiao Tong University School of Medicine Affilated Shang
May 2, 2023